AR124417A1 - Formulaciones de anticuerpos anti-il5r - Google Patents

Formulaciones de anticuerpos anti-il5r

Info

Publication number
AR124417A1
AR124417A1 ARP210103563A ARP210103563A AR124417A1 AR 124417 A1 AR124417 A1 AR 124417A1 AR P210103563 A ARP210103563 A AR P210103563A AR P210103563 A ARP210103563 A AR P210103563A AR 124417 A1 AR124417 A1 AR 124417A1
Authority
AR
Argentina
Prior art keywords
seq
set forth
chain variable
variable region
sequence set
Prior art date
Application number
ARP210103563A
Other languages
English (en)
Inventor
Saba Ghazvini
Cassandra Mankus
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of AR124417A1 publication Critical patent/AR124417A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions

Abstract

En el presente documento se proporcionan formulaciones de anticuerpos anti IL5R que contienen una cantidad de tensioactivo por debajo de la concentración de micela crítica (CMC) del tensioactivo y métodos para usar dichas formulaciones. Reivindicación 1: Una formulación farmacéutica, que comprende: (i) un anticuerpo o fragmento de unión a antígeno del mismo que comprende una CDR1 de región variable de cadena pesada que comprende la secuencia expuesta en la SEQ ID Nº 1; una CDR2 de región variable de cadena pesada que comprende la secuencia expuesta en la SEQ ID Nº 2; y una CDR3 de región variable de cadena pesada que comprende la secuencia expuesta en la SEQ ID Nº 3; una CDR1 de región variable de cadena ligera que comprende la secuencia expuesta en la SEQ ID Nº 4; una CDR2 de región variable de cadena ligera que comprende la secuencia expuesta en la SEQ ID Nº 5; y una CDR3 de región variable de cadena ligera que comprende la secuencia expuesta en la SEQ ID Nº 6; y (ii) un tensioactivo en una cantidad por debajo de la concentración micelar crítica (CMC) de dicho tensioactivo, en donde el tensioactivo no es polisorbato 20 (PS20).
ARP210103563A 2020-12-17 2021-12-17 Formulaciones de anticuerpos anti-il5r AR124417A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202063199277P 2020-12-17 2020-12-17

Publications (1)

Publication Number Publication Date
AR124417A1 true AR124417A1 (es) 2023-03-29

Family

ID=79316918

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP210103563A AR124417A1 (es) 2020-12-17 2021-12-17 Formulaciones de anticuerpos anti-il5r

Country Status (10)

Country Link
US (1) US20220193238A1 (es)
EP (1) EP4262868A1 (es)
JP (1) JP2023553641A (es)
KR (1) KR20230121797A (es)
CN (1) CN116887860A (es)
AR (1) AR124417A1 (es)
AU (1) AU2021404495A1 (es)
CA (1) CA3204307A1 (es)
IL (1) IL303744A (es)
WO (1) WO2022129301A1 (es)

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
WO1991010741A1 (en) 1990-01-12 1991-07-25 Cell Genesys, Inc. Generation of xenogeneic antibodies
CN1241944C (zh) 1995-09-11 2006-02-15 协和发酵工业株式会社 抗人白介素－5受体α链的抗体
NZ741494A (en) 2007-05-14 2022-11-25 Kyowa Kirin Co Ltd Methods of reducing eosinophil levels
WO2015038925A2 (en) * 2013-09-12 2015-03-19 Thomas Jefferson University Novel delivery compositions and methods of using same
EP3892288A1 (en) * 2013-10-24 2021-10-13 Astrazeneca AB Stable, aqueous antibody formulations
CA3059369A1 (en) * 2017-04-28 2018-11-01 Amgen Inc. N-acetylated and non-acetylated dipeptides containing arginine to reduce the viscosity of viscous compositions of therapeutic polypeptides
JP2022523510A (ja) * 2019-01-31 2022-04-25 エレクトロフィ，インコーポレイテッド 粒子形成及び形態構造

Also Published As

Publication number Publication date
CA3204307A1 (en) 2022-06-23
CN116887860A (zh) 2023-10-13
US20220193238A1 (en) 2022-06-23
AU2021404495A1 (en) 2023-07-27
IL303744A (en) 2023-08-01
JP2023553641A (ja) 2023-12-25
EP4262868A1 (en) 2023-10-25
KR20230121797A (ko) 2023-08-21
WO2022129301A1 (en) 2022-06-23

Similar Documents

Publication Publication Date Title
AR123876A2 (es) Composición farmacéutica de anticuerpos anti-cgrp
PE20120816A1 (es) Composiciones que comprenden anticuerpos de dickkopf-1
AR110203A1 (es) Anticuerpos anti-tim-3 para combinación con anticuerpos anti-pd-1
AR111630A1 (es) ANTICUERPOS ANTI-SIRPa
PE20110797A1 (es) Anticuerpos anti mn
CO2018010919A2 (es) Moleculas de unión b7-h3 novedosas, conjugados anticuerpo - fármaco de los mismos y métodos de uso de los mismos
AR099698A1 (es) Anticuerpos contra el c5 que tienen farmacocinética mejorada
PE20190970A1 (es) Anticuerpos anti-cd40 y sus usos
PE20141432A1 (es) Anticuerpos neutralizantes de citomegalovirus humano
PE20120475A1 (es) Anticuerpos especificos para dkk-1
CL2016000324A1 (es) Anticuerpos monoclonales que se unen especificamente al inhibidor del activador de plasminogeno de tipo 1 (pai-1); y uso para preparar un medicamento util para restaurar la generación de plasmina o tratar una afeccion causada por el aumento de los niveles de pai-1 o el aumento de la sensibilidad a pai-1.
AR115365A1 (es) Formulaciones de anticuerpos anti-pd-l1 humanos
PE20131209A1 (es) Anticuerpos anti-fap
RU2014108047A (ru) Фармацевтическая композиция для лечения и/или профилактики рака поджелудочной железы
PE20120079A1 (es) Moleculas de anticuerpos mejoradas
AR110719A1 (es) Anticuerpos humanos a la toxina hemolisina a de s. aureus
AR127344A2 (es) Conjugados anticuerpo-fármaco que comprenden agonistas de sting
PE20221263A1 (es) Agentes de union a ilt3 y metodos de uso de los mismos
PE20121494A1 (es) Anticuerpos anti notch-1
AR096601A1 (es) Anticuerpos del receptor 1 de ldl oxidado similar a lectina y métodos de uso
ES2721378T3 (es) Anticuerpos anti-TLR4 y métodos de uso de los mismos
AR105978A1 (es) Moléculas de unión a linfopoyetina estromal tímica (tslp) y métodos de uso de las moléculas
PE20201503A1 (es) Formulaciones de inmunoconjugado anti-cd79b estables
AR110967A1 (es) Anticuerpos miméticos fgf21 y su uso
AR111764A1 (es) Proteína de unión a antígeno, anticuerpo que la comprende, cadena peptídica comprendida en el anticuerpo y composiciones relacionadas